BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-06-27 pm EDT
213.57 USD   +0.77%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société BIOGEN INC.
06/22Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
AQ
06/22Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
BU
06/21BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote o..
AQ
06/21European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)
GL
06/16Biogen Inc. - New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA P..
AQ
06/15BIOGEN : Annual Stockholder Presentation 2022
PU
06/15BIOGEN : Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner
PU
06/15New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
GL
06/15New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
AQ
06/14The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
GL
06/08Biogen And Samsung Bioepis Launch BYOOVIZ (ranibizumab-nuna)
AQ
06/08BIOGEN : Withdrawal from the Jefferies Healthcare Conference
PU
06/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
06/06Biogen Inc. - New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Me..
AQ
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
GL
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
AQ
06/03Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
GL
06/03Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
06/03New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
GL
06/03New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
AQ
06/02Biogen and Samsung Bioepis' BYOOVIZ™ (ranibizumab-nuna) Launches in the United St..
AQ
05/31Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor..
AQ
05/27BIOGEN : to Participate in the Jefferies Healthcare Conference
PU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/03BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
05/03Change at the top for Biogen after Alzheimer's drug flops
AQ
05/03BIOGEN INC. : Results of Operations and Financial Condition, Change in Directors or Princi..
AQ
05/03BIOGEN : Reports First Quarter 2022 Results
PU
05/03BIOGEN : Q1 2021 Biogen Earnings Presentation
PU
04/29BIOGEN : Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in..
PU
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/22BIOGEN : Update on Regulatory Submission for Aducanumab in the European Union
PU
04/20BIOGEN : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics f..
PU
04/07BIOGEN : Statement on the Final National Coverage Determination for Amyloid-Beta Targeting..
PU
04/05BIOGEN : to Report First Quarter 2022 Financial Results May 3, 2022
PU
04/04New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerg..
AQ
03/30Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to ..
AQ
03/28Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9or..
AQ
03/23Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE..
AQ
03/22Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship t..
AQ
03/18BIOGEN : The National Minority Quality Forum and Biogen Highlight Equitable Access to Rese..
PU
03/17BIOGEN : to Participate in the Stifel 2022 CNS Days
PU
03/17Biogen Announces Peer-Reviewed Publication of ADUHELM Phase 3 EMERGE and ENGAGE Data in..
AQ
03/17Long-Term Phase 3 Data Show ADUHELM Continues to Reduce Underlying Pathologies of Alzhe..
AQ
03/16Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data i..
GL
03/16Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data i..
GL
03/16Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzh..
AQ
03/15Eisai - ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER'S DISEASE TREATMENT COLLABORATI..
AQ
03/14Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
AQ
03/14Biogen to Present New Research at the International Conference on Alzheimer's and Parki..
AQ
03/14Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
AQ
03/11Biogen to Present New Research at the International Conference on Alzheimer's and Parki..
AQ
03/07Eisai initiates submission of application data under the prior assessment consultation ..
AQ
03/03BIOGEN INC. COMPANY NEWS : Berger Montague Investigates Securities Fraud Allegations Again..
PR
03/03Eisai initiates submission of application data under the prior assessment consultation ..
PR
02/24Xbrane Biopharma releases Year-end report 2021
AQ
02/18BIOGEN : to Present at the Cowen 42nd Annual Health Care Conference
PU
02/17Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key S..
AQ
02/17Biogen And Xbrane Enter Into Worldwide Commercialization And License Agreement For Cert..
AQ
02/11Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Propose..
AQ
02/10BIOGEN : Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed..
PU
02/08Biogen and xbrane announce commercialization and license agreement for proposed biosimi..
AQ
02/07Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimi..
AQ
02/04Biogen reports fourth quarter and full year 2021 results
AQ
02/03BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
02/03Biogen's 2022 outlook leaves investors wanting, shares slip
AQ
02/03BIOGEN : Q4 2021 Biogen Earnings Presentation
PU
02/03BIOGEN : REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS - Form 8-K
PU
02/03BIOGEN : Reports Q4 2021 Earnings
PU
02/01Biogen Exercises Option to Participate in the Development and Commercialization of a La..
AQ
01/31BIOGEN : Announces Nancy Leaming and Brian Posner to Retire from Board of Directors - Form..
PU
01/31BIOGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BIOGEN INC.